Home > Insider Trading > Filing (0001179110-18-004708)

Filing Details

Accession Number:: 0001179110-18-004708
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-03-20 20:02:29
Reporting Period:: 2018-03-16

Accepted Time:: 2018-03-20 20:02:29
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1597264	Blueprint Medicines Corp	BPMC	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1663022	Kate Haviland	C/O Blueprint Medicines Corporation 45 Sidney Street Cambridge MA 02139	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-03-16	1,571	$16.28	7,445	No	4	M	Direct
Common Stock	Acquisiton	2018-03-16	2,500	$36.05	9,945	No	4	M	Direct
Common Stock	Disposition	2018-03-16	500	$102.19	9,445	No	4	S	Direct
Common Stock	Disposition	2018-03-16	1,800	$101.32	7,645	No	4	S	Direct
Common Stock	Disposition	2018-03-16	1,200	$100.02	6,445	No	4	S	Direct
Common Stock	Disposition	2018-03-16	571	$99.20	5,874	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2018-03-16	1,571	$0.00	1,571	$16.28
Common Stock	Stock Option (Right to Buy)	Disposition	2018-03-16	2,500	$0.00	2,500	$36.05

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
120,639		2026-02-01	No	4	M	Direct
118,139		2027-02-16	No	4	M	Direct

Footnotes

The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.90 to $102.84 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.98 to $101.80 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.66 to $100.54 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.73 to $99.50 per share.
This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.
This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.